KRAS and Miyoshi myopathy: Among them, AZD4785 stands out as a highly efficient and selective KRAS-targeting antisense oligonucleotide, capable of specifically silencing KRAS and significantly inhibiting MM tumor growth both in vitro and in vivo [99].